Location: Franklin/Nashville, Tennessee, United States
LinkedIn: [DW Kingma](https://www.linkedin.com/in/dw-kingma-985313284)
Professional Role and Affiliation
Dr. Douglas W. Kingma serves as the Medical Director of HMS Laboratories at Tennessee Oncology, a prominent oncology practice based in Tennessee. His role encompasses leadership in hematopathology and molecular diagnostic services critical to oncology patient care. The laboratory under his direction supports precise cancer diagnosis and personalized treatment approaches, aligning with Tennessee Oncology’s patient-centered operational model.
Medical Expertise and Specialization
Dr. Kingma is a board-certified pathologist specializing in molecular genetic pathology with over 38 years of clinical experience. His subspecialty expertise includes hematopathology, oncology pathology, surgery, and hematology, indicating a broad and deep understanding of cancer biology, diagnostic pathology, and related clinical disciplines.
He completed his medical degree in 1987 at Sidney Kimmel Medical College at Thomas Jefferson University, followed by a residency in anatomic and clinical pathology at New York-Presbyterian/Weill Cornell Medical Center. He further pursued a hematopathology fellowship at the University of New Mexico School of Medicine, focusing on advanced diagnostic methods for hematologic malignancies.
Clinical and Operational Context
Practicing primarily out of Franklin, TN, Dr. Kingma is affiliated with Tennessee Oncology and associated facilities such as Ascension Saint Thomas Hospital. His diagnostic acumen supports laboratory services integral to treatment planning, including the application of molecular and hematopathologic techniques critical in contemporary oncology and personalized medicine.
Tennessee Oncology is recognized for expanding leadership in comprehensive cancer care, with Dr. Kingma’s laboratory directorship closely aligned to advancing precision diagnostics. This enhances clinical decision-making, therapeutic targeting, and patient outcomes via advanced laboratory testing and molecular analyses.
Academic Contributions and Publications
Though specific detailed bibliographic records are limited, Dr. Kingma has contributed to scientific literature with at least three cited publications related to oncologic pathology. These involve diagnostic assays for viral genotyping in cancers and molecular characterization of malignancies.
His involvement in evidence-based medicine and clinical research is underscored by his participation in advancement of diagnostic methodologies, particularly in hematopathology and molecular oncology arenas. Further research highlights point to application of biomarkers and genetic data in cancer diagnosis and prognosis, which presumably informs his clinical laboratory leadership at Tennessee Oncology.
Recognition and Ranking
Dr. Kingma is ranked 5th out of 58 pathology doctors in the local Tennessee area and holds a national ranking of 752 out of 11,846 pathologists, demonstrating recognized expertise within his specialty at both regional and national levels. His longstanding clinical tenure and educational background position him as an authoritative figure in molecular pathology within Tennessee Oncology's network.
Contact and Practice Information
- Office Location: 4488 Carothers Parkway, Suite 310, Franklin, TN 37067
- Contact Phone: +1 615-406-1626 (associated with Tennessee Oncology laboratory services)
- Additional Office Phone: 615-986-4330 (primary pathology practice line)
Professional Network and Influence
Dr. Kingma maintains approximately 44 followers and 43 connections on LinkedIn, primarily healthcare professionals, indicating engagement within a specialized professional network. He actively recognizes and supports peers’ leadership advancements within Tennessee Oncology, reflecting integration in an evolving clinical leadership environment.
This profile confirms Dr. Kingma’s critical role as a senior clinical and laboratory leader within Tennessee Oncology, with specialized expertise in molecular genetic pathology and hematopathology fundamental to the institution’s cancer diagnostic and treatment services. Understanding his clinical and operational remit supports targeted engagement that aligns with laboratory-driven, precision oncology initiatives.
